The Jan 5 PR said, "results of the (NASH) topline
Post# of 154089
(Total Views: 560)
Posted On: 03/07/2022 12:51:08 PM
Re: nmbr1stckpckr #119605
The Jan 5 PR said, "results of the (NASH) topline report will be announced when available".
Throw out all the BS Nader timeline promises and that's what a company normally says. And normally it takes time to process data and generate a report (hopefully not NWBO time, but time nonetheless).
Add in the fact that there were 12 endpoints (although I believe tests were only done twice for each) and that Recknor said "we are in the process of analyzing biomarker data including CCR5 haplotype information to better understand responder rates and mechanism of action", plus the distractions of the turmoil around the leadership change and money issues...I think it's reasonable to think that the NASH analysis is still in process.
Hopefully the publication of the results is being held up by some kind of licensing deal, or by shopping for a deal, but it seems very plausible that we haven't gotten a topline report yet simply because the scientific team is still working on putting it all together.
Throw out all the BS Nader timeline promises and that's what a company normally says. And normally it takes time to process data and generate a report (hopefully not NWBO time, but time nonetheless).
Add in the fact that there were 12 endpoints (although I believe tests were only done twice for each) and that Recknor said "we are in the process of analyzing biomarker data including CCR5 haplotype information to better understand responder rates and mechanism of action", plus the distractions of the turmoil around the leadership change and money issues...I think it's reasonable to think that the NASH analysis is still in process.
Hopefully the publication of the results is being held up by some kind of licensing deal, or by shopping for a deal, but it seems very plausible that we haven't gotten a topline report yet simply because the scientific team is still working on putting it all together.
(2)
(0)